Published in Br J Pharmacol on March 01, 2002
No hypothermic response to serotonin in 5-HT7 receptor knockout mice. Proc Natl Acad Sci U S A (2003) 1.20
Biphasic regulation of mammary epithelial resistance by serotonin through activation of multiple pathways. J Biol Chem (2008) 1.13
Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol Ther (2010) 1.05
The role of central 5-hydroxytryptamine (5-HT, serotonin) receptors in the control of micturition. Br J Pharmacol (2006) 1.05
The serotonin 5-HT7 receptors: two decades of research. Exp Brain Res (2013) 1.01
Quantitative measurement of cAMP concentration using an exchange protein directly activated by a cAMP-based FRET-sensor. Biophys J (2008) 0.94
Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.92
Human 5-HT(4) and 5-HT(7) receptor splice variants: are they important? Curr Neuropharmacol (2007) 0.83
In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. PLoS One (2016) 0.82
Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.81
Alternative Splicing of G Protein-Coupled Receptors: Relevance to Pain Management. Mayo Clin Proc (2015) 0.81
Effect of methysergide on pudendal inhibition of micturition reflex in cats. Exp Neurol (2013) 0.80
Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.79
Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br J Pharmacol (2006) 0.79
Antagonist interaction with the human 5-HT(7) receptor mediates the rapid and potent inhibition of non-G-protein-stimulated adenylate cyclase activity: a novel GPCR effect. Br J Pharmacol (2011) 0.79
5-HT7 receptor efficacy distribution throughout the canine stomach. Br J Pharmacol (2004) 0.77
Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.77
The atypical antipsychotics clozapine and olanzapine promote down-regulation and display functional selectivity at human 5-HT7 receptors. Br J Pharmacol (2015) 0.75
Activation of 5-hyrdoxytryptamine 7 receptors within the rat nucleus tractus solitarii modulates synaptic properties. Brain Res (2016) 0.75
Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science (1997) 8.16
Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature (1997) 7.92
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev (1994) 7.11
A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem (1993) 4.52
The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature (1998) 3.41
Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature (1993) 2.91
Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J (2001) 2.51
Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol (1994) 2.22
Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci (1997) 1.47
Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem (2000) 1.38
Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. J Biol Chem (1999) 1.33
Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing. Mol Pharmacol (1996) 1.27
Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol (1999) 1.24
Changes in the carboxyl-terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist-independent activity. Mol Pharmacol (1996) 1.21
Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization. J Neurochem (1997) 1.20
The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.20
Two isoforms of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization. J Biol Chem (1993) 1.19
Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br J Pharmacol (1997) 1.15
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br J Pharmacol (1998) 1.10
Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J Neurochem (1998) 1.09
5-HT1-like receptors: a time to bid goodbye. Trends Pharmacol Sci (1998) 1.09
5-HT7 receptors: current knowledge and future prospects. Trends Pharmacol Sci (2000) 1.08
The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. EMBO J (1995) 1.07
The 5-HT7 receptor: orphan found. Trends Pharmacol Sci (1997) 1.07
Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant. J Neurochem (2000) 1.07
Modulation of forskolin-mediated adenylyl cyclase activation by constitutively active G(S)-coupled receptors. FEBS Lett (1997) 0.98
Function and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing. Neuropharmacology (1998) 0.97
The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization. FEBS Lett (1993) 0.95
The PACAP receptor: generation by alternative splicing of functional diversity among G protein-coupled receptors in nerve cells. Semin Cell Biol (1994) 0.92
Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human beta 2-adrenoceptor. Mol Pharmacol (1995) 0.92
Pharmacological properties of 5-Hydroxytryptamine(4) receptor antagonists on constitutively active wild-type and mutated receptors. Mol Pharmacol (2000) 0.91
Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation. J Pharmacol Exp Ther (1998) 0.89
Distinct receptor domains determine subtype-specific coupling and desensitization phenotypes for human beta1- and beta2-adrenergic receptors. Mol Pharmacol (1996) 0.89
Restricting mobility of Gsalpha relative to the beta2-adrenoceptor enhances adenylate cyclase activity by reducing Gsalpha GTPase activity. Biochem J (1998) 0.86
Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry. Mol Pharmacol (2000) 0.84
Examining the efficiency of receptor/G-protein coupling with a cleavable beta2-adrenoceptor-gsalpha fusion protein. Eur J Biochem (1999) 0.83
Constitutive activation of muscarinic receptors by the G-protein Gq. FEBS Lett (1995) 0.82
Overexpression of G(s)alpha in NG108-15, neuroblastomaXglioma cells: effects on receptor regulation of the stimulatory adenylyl cyclase cascade. FEBS Lett (1996) 0.81
Distinct function of the cytoplasmic tail in human D1-like receptor ligand binding and coupling. FEBS Lett (2000) 0.81
Efficacy of inverse agonists in cells overexpressing a constitutively active beta2-adrenoceptor and type II adenylyl cyclase. Br J Pharmacol (1998) 0.81
Short term storage of samples containing monoamines: ascorbic acid and glutathione give better protection against degradation than perchloric acid. J Neurosci Methods (1997) 0.76
Rapid desensitization of the TRH receptor and persistent desensitization of its constitutively active mutant. Br J Pharmacol (2000) 0.76
5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther (2006) 1.53
Diastolic dysfunction in alveolar hypoxia: a role for interleukin-18-mediated increase in protein phosphatase 2A. Cardiovasc Res (2008) 1.49
Identification of small molecule NPR-B antagonists by high throughput screening--potential use in heart failure. Naunyn Schmiedebergs Arch Pharmacol (2013) 1.39
Reference gene alternatives to Gapdh in rodent and human heart failure gene expression studies. BMC Mol Biol (2010) 1.09
Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc Res (2005) 1.03
The serotonin 5-HT7 receptors: two decades of research. Exp Brain Res (2013) 1.01
Expression of mRNA encoding G protein-coupled receptors involved in congestive heart failure--a quantitative RT-PCR study and the question of normalisation. Basic Res Cardiol (2007) 1.00
Heterologous desensitization is evoked by both agonist and antagonist stimulation of the human 5-HT(7) serotonin receptor. Eur J Pharmacol (2006) 0.98
Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists. Bioorg Med Chem (2010) 0.96
Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.96
NSC23766, a widely used inhibitor of Rac1 activation, additionally acts as a competitive antagonist at muscarinic acetylcholine receptors. J Pharmacol Exp Ther (2013) 0.95
Ras-dependent ERK activation by the human G(s)-coupled serotonin receptors 5-HT4(b) and 5-HT7(a). J Biol Chem (2002) 0.95
Serotonin responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle. J Mol Cell Cardiol (2007) 0.93
Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate (2008) 0.92
Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res (2009) 0.90
Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i). Naunyn Schmiedebergs Arch Pharmacol (2004) 0.90
Activation of adenylyl cyclase by endogenous G(s)-coupled receptors in human embryonic kidney 293 cells is attenuated by 5-HT(7) receptor expression. Mol Pharmacol (2005) 0.87
Substrate specificities of g protein-coupled receptor kinase-2 and -3 at cardiac myocyte receptors provide basis for distinct roles in regulation of myocardial function. Mol Pharmacol (2007) 0.87
PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br J Pharmacol (2013) 0.87
Dual serotonergic regulation of ventricular contractile force through 5-HT2A and 5-HT4 receptors induced in the acute failing heart. Circ Res (2005) 0.86
Prostanoid-mediated inotropic responses are attenuated in failing human and rat ventricular myocardium. Eur J Pharmacol (2012) 0.85
Endogenous expression and protein kinase A-dependent phosphorylation of the guanine nucleotide exchange factor Ras-GRF1 in human embryonic kidney 293 cells. FEBS J (2005) 0.85
Functional 5-HT receptors in human occipital artery. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.85
The heterotrimeric G-protein alpha-subunit Galphaq regulates TCR-mediated immune responses through an Lck-dependent pathway. Eur J Immunol (2008) 0.85
Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.84
Unaltered agonist potency upon inducible 5-HT7(a) but not 5-HT4(b) receptor expression indicates agonist-independent association of 5-HT7(a) receptor and Gs. Receptors Channels (2003) 0.84
Retinoic acid signalling is activated in the postischemic heart and may influence remodelling. PLoS One (2012) 0.83
Disheveled regulates precoupling of heterotrimeric G proteins to Frizzled 6. FASEB J (2014) 0.83
Alpha1-AR-mediated activation of NKCC in rat cardiomyocytes involves ERK-dependent phosphorylation of the cotransporter. Am J Physiol Heart Circ Physiol (2003) 0.81
Differential regulation of β2 -adrenoceptor-mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non-failing rat cardiac ventricle. Br J Pharmacol (2011) 0.81
Cardiomyocyte-restricted inhibition of G protein-coupled receptor kinase-3 attenuates cardiac dysfunction after chronic pressure overload. Am J Physiol Heart Circ Physiol (2012) 0.81
Agents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.81
The cardiac ventricular 5-HT4 receptor is functional in late foetal development and is reactivated in heart failure. PLoS One (2012) 0.80
Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.80
Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. Eur J Heart Fail (2009) 0.80
Serotonin increases L-type Ca2+ current and SR Ca2+ content through 5-HT4 receptors in failing rat ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol (2007) 0.79
Non-classical regulation of β1- and β 2-adrenoceptor-mediated inotropic responses in rat heart ventricle by the G protein Gi. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.79
Cloning, genomic organization and functionality of 5-HT(7) receptor splice variants from mouse brain. Gene (2008) 0.79
Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.78
Fading of 5-HT4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium. Br J Pharmacol (2006) 0.78
EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase. Cell Signal (2008) 0.78
Quantification of GPCR mRNA using real-time RT-PCR. Methods Mol Biol (2011) 0.78
RAMP2 and RAMP3 mRNA levels are increased in failing rat cardiomyocytes and associated with increased responsiveness to adrenomedullin. J Mol Cell Cardiol (2004) 0.78
Prostanoid F receptors elicit an inotropic effect in rat left ventricle by enhancing myosin light chain phosphorylation. Cardiovasc Res (2008) 0.77
Connective tissue growth factor/CCN2 attenuates β-adrenergic receptor responsiveness and cardiotoxicity by induction of G protein-coupled receptor kinase-5 in cardiomyocytes. Mol Pharmacol (2013) 0.77
Acidic biphenyl derivatives: synthesis and biological activity of a new series of potent 5-HT(4) receptor antagonists. Bioorg Med Chem (2013) 0.76
Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist. Eur J Med Chem (2013) 0.75
Novel benzo[b]thiophene derivatives as new potential antidepressants with rapid onset of action. J Med Chem (2011) 0.75
Epac- and Rap- independent ERK1/2 phosphorylation induced by Gs-coupled receptor stimulation in HEK293 cells. FEBS Lett (2006) 0.75
Prostaglandin E1 facilitates inotropic effects of 5-HT4 serotonin receptors and β-adrenoceptors in failing human heart. Basic Res Cardiol (2012) 0.75
Calculating reaction rate constants and estimating the efficacy of selective enzyme inhibitors. Anal Biochem (2008) 0.75